First safety test for liver drug in damaged livers
NCT ID NCT06825559
Summary
This is an early safety study to see how a drug called saroglitazar magnesium is processed by the body in people who have moderate liver damage from a specific type of liver disease. It will involve 6 participants who have this condition. The main goal is to measure drug levels in the blood and check for side effects when the drug is taken every other day.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLESTATIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zydus Site US001
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.